Introduction
An ovarian cyst is a common condition seen in clinical practice and is a common cause of pelvic/adnexal masses [1] . Giant ovarian cysts, on the other hand, are rare findings in current clinical practice. Historically, ovarian cysts measuring up to 148.6 kg (328 lb) have been recorded in the medical literature [2] .
Advancement in imaging modalities and routine physical examinations have enabled clinicians to diagnose ovarian cysts while they are at a relatively smaller size. Giant cysts are often misdiagnosed due to their vague symptoms and non-specific findings. Also, a delay in diagnosis, especially among asymptomatic patients, is seen due to their varied presentations.
Case Presentation
Our patient is a 58-year-old Caucasian female with a past medical history of hypertension, hyperlipidemia, class III obesity, diabetes mellitus, tobacco use, obstructive sleep apnea, gastroesophageal reflux disease, and hypothyroidism who presented to the Family Medicine clinic for evaluation of vague abdominal symptoms, such as constipation, abdominal discomfort, bloating, as well as intermittent postmenopausal bleeding, for the past six to eight months.
She denied being sexually active for the last five years. She did not endorse vaginal discharge, fever, chills, abdominal pain, flank pain, dysuria, hematuria, pelvic discomfort, low back pain, or noncompliance with thyroid medication. Gynecologic history was significant for menarche at age 12 and premature menopause at age 38, and surgical history was significant for having undergone a cesarean section at 30 years of age. Family history was significant for lymphoma in mother, breast cancer in paternal aunt, and pancreatic cancer in maternal grandmother.
During her office visit, her pelvic exam revealed a normal bimanual exam without masses, fullness, or cervical motion tenderness. The uterus was normal by palpation. Papanicolaou smear was also done at this visit. Her cervical cytology was negative for any intraepithelial lesion as well and negative for high-risk HPV.
Lab work, including thyroid-stimulating hormone (TSH), complete blood count (CBC), comprehensive metabolic panel (CMP), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were unremarkable. Her bilateral mammogram was reported as being benign.
Transvaginal ultrasound was significant for bilateral multilocular cystic masses with thin septations and hypoechoic fluid suspicious for serous or mucinous cystadenoma and thickened endometrium of 17 mm.
Magnetic resonance imaging (MRI) without contrast of the pelvis confirmed bilateral multicystic ovarian masses measuring 16 x 10 cm and 17 x 9 cm with the presence of thick septations and papillary-like projections (Figures 1-2 ). The patient was referred to the outpatient obstetrics and gynecology clinic for further management, where she underwent an endometrial biopsy that revealed benign findings. 
Discussion Epidemiology
Ovarian cysts are a very commonly encountered condition in females [1] . Worldwide, about 7% of women are reported to have an ovarian cyst at any point in their life. Studies have reported the rates of ovarian cyst in postmenopausal women in the United States and Europe to be 18% and about 21%, respectively [3] .
Giant ovarian cysts, which are generally described as more than 10 centimeters in size in their largest diameter [4] , are rare in occurrence. Due to rarity and a lack of standardized definition, the incidence or prevalence rate of a giant ovarian tumor could not be ascertained. Giant ovarian cysts are seen more frequently between the third and sixth decades of life [5] [6] . A review of the literature does show sporadic case reports of these cysts, especially in postmenopausal women [7] [8] [9] [10] [11] .
Demography
Per the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are categorized into three types of tumors: epithelial (60%), germ cell (30%), and sex-cord stromal (8%) [12] . The ovarian epithelial tumors make up about 50% of all ovarian tumors, with about 40% benign and 86% malignant [9] .
Benign serous tumors, which include cystadenomas, adenofibromas, and surface papillomas, account for about 25% of all benign ovarian tumors and 58% of all serous ovarian tumors [7, 9] .
Ovarian serous tumors are bilateral in 10% of patients. Of all serous tumors, about 70% are benign, 5%-10% have borderline malignant potential, and 20%-25% are frankly malignant. They tend to be multilocular and can include papillary projections but unilocular serous cystadenomas are not uncommon [6] .
A review of racial distribution revealed that malignant epithelial cystadenomas were highest among American Indian women, followed by white, Vietnamese, Hispanic, and Hawaiian women. The incidence is lowest among Korean and Chinese women. However, no data for ovarian cysts could be obtained [13] .
Clinical presentation
These masses can have a wide range of presentations that a clinician needs to be aware of. They can be entirely asymptomatic [14] , or patients can present with a myriad of gastrointestinal manifestations, including nausea, abdominal pain, fullness or discomfort, or abdominal swelling and distension to even massive ascites [4, 8, 10, [15] [16] . In some cases, it can even masquerade as pregnancy in a patient of childbearing age [4] . In the elder patient, it can present with low backache, difficulty walking, anorexia, and generalized weakness [8, 9, 16] . The large tumor mass can also cause tachypnea and dyspnea, especially on recumbency [15] .
Differential diagnoses
The differential diagnoses of giant ovarian cysts are extensive and can include benign and malignant gynecologic and non-gynecologic diagnoses [17] ranging from a distended bladder, hydronephrosis, ascites, accentuated obesity, pregnancy, fibroids, and intra-abdominal and adnexal masses.
Diagnosis
After the initial clinical evaluation, imaging modalities, such as transvaginal and transabdominal ultrasonography, computed tomography (CT), and MRI of the abdomen and pelvis are used to corroborate the diagnosis [4] [5] [7] [8] [9] [10] 12, 15] . Clinicians can utilize the Risk of Ovarian Malignancy algorithm to determine the malignant potential of the mass and plan the management accordingly. The frozen sections and, subsequently, the histopathological evaluation will give the confirmatory diagnosis. Additional testing, such as Papanicolaou smear and endometrial sampling, would be needed.
Tumor markers
To detect the potential malignancy associated with ovarian tumors, tumor markers can be used preoperatively. CA-125, also known as mucin16, is a widely used marker and is useful in distinguishing malignant from benign pelvic masses. If a postmenopausal patient with an adnexal mass has serum CA-125 levels above 200 U/mL, the positive predictive value is of it being malignant is 96% [18] . In premenopausal patients, however, the specificity of the test is low, as the levels tend to be elevated in benign conditions as well [18] . It has been found to help in the early diagnosis of epithelial ovarian cancer with a sensitivity of 50% for patients with stage I disease [18] .
Human epididymis protein 4 (HE-4) has shown superiority over CA-125 as a biomarker, specifically with its higher sensitivity to distinguish benign diseases from malignancies [19] .
Management
The mainstay of treatment is the removal of the mass. This requires proper planning of the modality of approach, which can include en bloc removal versus slow percutaneous drainage. The approach depends on the size and skills of the operating surgeon while keeping in mind the risks of the development of potential surgical complications.
Conclusions
Giant ovarian cysts are rare findings in current clinical practice, as advancement in imaging modalities and routine physical examinations have enabled clinicians to diagnose them while they are at a relatively smaller size. Our patient had predominantly vague gastrointestinal symptoms, completely unrelated to the actual diagnosis. This case highlights the importance of considering giant ovarian cysts as a differential diagnosis of vague abdominal symptoms, as these patients can have varied presentations.
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